| First Author | Akerman I | Year | 2021 |
| Journal | Cell Rep | Volume | 35 |
| Issue | 2 | Pages | 108981 |
| PubMed ID | 33852861 | Mgi Jnum | J:308553 |
| Mgi Id | MGI:6728344 | Doi | 10.1016/j.celrep.2021.108981 |
| Citation | Akerman I, et al. (2021) Neonatal diabetes mutations disrupt a chromatin pioneering function that activates the human insulin gene. Cell Rep 35(2):108981 |
| abstractText | Despite the central role of chromosomal context in gene transcription, human noncoding DNA variants are generally studied outside of their genomic location. This limits our understanding of disease-causing regulatory variants. INS promoter mutations cause recessive neonatal diabetes. We show that all INS promoter point mutations in 60 patients disrupt a CC dinucleotide, whereas none affect other elements important for episomal promoter function. To model CC mutations, we humanized an approximately 3.1-kb region of the mouse Ins2 gene. This recapitulated developmental chromatin states and cell-specific transcription. A CC mutant allele, however, abrogated active chromatin formation during pancreas development. A search for transcription factors acting through this element revealed that another neonatal diabetes gene product, GLIS3, has a pioneer-like ability to derepress INS chromatin, which is hampered by the CC mutation. Our in vivo analysis, therefore, connects two human genetic defects in an essential mechanism for developmental activation of the INS gene. |
